Genexine Inc (095700) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.011x

Based on the latest financial reports, Genexine Inc (095700) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion ≈ $-2.02 Million USD) by net assets (₩260.01 Billion ≈ $176.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 095700 equity to assets ratio to measure how much of total assets are equity-financed.

Genexine Inc - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Genexine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Genexine Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Genexine Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genexine Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
LUOYANG GLASS CO. H YC 1 F:LUG	N/A
Thac Ba Hydropower JSC VN:TBC	0.057x
Chasys KO:033250	0.076x
Namu Tech Co.Ltd KQ:242040	0.094x
Tamawood Ltd AU:TWD	0.257x
Renergen Ltd. JSE:REN	-0.171x
WeConnect PA:ALWEC	0.183x
Mastech Holdings Inc NYSE MKT:MHH	0.074x

Annual Cash Flow Conversion Efficiency for Genexine Inc (2009–2024)

The table below shows the annual cash flow conversion efficiency of Genexine Inc from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Genexine Inc market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩261.68 Billion ≈ $177.34 Million	₩-1.65 Billion ≈ $-1.12 Million	-0.006x	+95.09%
2023-12-31	₩296.90 Billion ≈ $201.21 Million	₩-38.05 Billion ≈ $-25.79 Million	-0.128x	+11.07%
2022-12-31	₩276.15 Billion ≈ $187.15 Million	₩-39.80 Billion ≈ $-26.97 Million	-0.144x	-485.45%
2021-12-31	₩517.74 Billion ≈ $350.87 Million	₩-12.75 Billion ≈ $-8.64 Million	-0.025x	+41.89%
2020-12-31	₩535.60 Billion ≈ $362.97 Million	₩-22.69 Billion ≈ $-15.38 Million	-0.042x	+69.74%
2019-12-31	₩296.91 Billion ≈ $201.21 Million	₩-41.57 Billion ≈ $-28.17 Million	-0.140x	-123.77%
2018-12-31	₩320.51 Billion ≈ $217.20 Million	₩-20.05 Billion ≈ $-13.59 Million	-0.063x	+72.70%
2017-12-31	₩113.91 Billion ≈ $77.19 Million	₩-26.10 Billion ≈ $-17.69 Million	-0.229x	-176.72%
2016-12-31	₩170.24 Billion ≈ $115.37 Million	₩-14.10 Billion ≈ $-9.55 Million	-0.083x	-534.09%
2015-12-31	₩125.77 Billion ≈ $85.23 Million	₩-1.64 Billion ≈ $-1.11 Million	-0.013x	-135.88%
2012-12-31	₩45.83 Billion ≈ $31.06 Million	₩1.67 Billion ≈ $1.13 Million	0.036x	+125.17%
2011-12-31	₩24.04 Billion ≈ $16.29 Million	₩-3.48 Billion ≈ $-2.36 Million	-0.145x	+17.18%
2010-12-31	₩26.43 Billion ≈ $17.91 Million	₩-4.62 Billion ≈ $-3.13 Million	-0.175x	-19184.88%
2009-12-31	₩38.50 Billion ≈ $26.09 Million	₩35.23 Million ≈ $23.87K	0.001x	--

About Genexine Inc

KQ:095700 Korea Biotechnology

Market Cap

$75.97 Million

₩112.11 Billion KRW

Market Cap Rank

#20194 Global

#1039 in Korea

Share Price

₩2465.00

Change (1 day)

+5.34%

52-Week Range

₩2195.00 - ₩7100.00

All Time High

₩131402.78